Get the Stockscreener App
351.40
1.01%
-3.90
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $351.40, with a volume of 781.61K.
It is down -1.01% in the last 24 hours and up +1.12% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$355.30
Open:
$354.25
24h Volume:
781.61K
Relative Volume:
0.28
Market Cap:
$189.44B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
24.69
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
+0.54%
1M Performance:
+1.12%
6M Performance:
+15.95%
1Y Performance:
+26.84%
1-Day Range:
$351.23
$356.90
1-Week Range:
$344.21
$356.90
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
351.43 | 191.53B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
925.34 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
232.44 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
205.32 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
201.96 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
118.20 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Zurcher Kantonalbank Zurich Cantonalbank Buys 55,333 Shares of Amgen Inc. $AMGN - MarketBeat
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer - GlobeNewswire Inc.
Pfizer (PFE) and Amgen (AMGN) Expand Presence in Hong Kong - GuruFocus
Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP (PFE:NYSE) - Seeking Alpha
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to unlock new upside? - AD HOC NEWS
Amgen Inc. Trade Ideas — LSE:0R0T - TradingView
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to drive sustained upside? - AD HOC NEWS
Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer Therapy - Insider Monkey
Wealth Enhancement Trust Services Inc. Takes $1.58 Million Position in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reconsider Amgen (AMGN) After Its Strong Multi Year Share Price Run? - Yahoo Finance
Amgen Inc. stock (US0311621009): Is its obesity drug pipeline strong enough to unlock new upside? - AD HOC NEWS
Oak Harvest Investment Services Reduces Stake in Amgen Inc. $AMGN - MarketBeat
GF Fund Management CO. LTD. Acquires 6,216 Shares of Amgen Inc. $AMGN - MarketBeat
Asset Management One Co. Ltd. Has $114.31 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Laps the Stock Market: Here's Why - Yahoo Finance Singapore
AMGEN INC: SUBMITS SEC FILING FOR COMMON STOCK OFFERING BY SELLING SECURITYHOLDERS - Intellectia AI
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
UBS Sees Continued Upside in Amgen (AMGN), Lifts Target to $400 - Insider Monkey
Amgen Inc. $AMGN Shares Sold by Whittier Trust Co. - MarketBeat
Mirae Asset Global Investments Co. Ltd. Has $186.70 Million Stake in Amgen Inc. $AMGN - MarketBeat
Assessing Whether Amgen (AMGN) Still Looks Undervalued After Recent Share Price Pullback - simplywall.st
Argo Wealth Advisory LLC Purchases New Shares in Amgen Inc. $AMGN - MarketBeat
AE Wealth Management LLC Has $43.90 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Federal Circuit Distinguishes Amgen in Reversal of Invalidation of Teva Headache Treatment Patents - IPWatchdog.com
Idiopathic Pulmonary Fibrosis Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GSK, Amgen, Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant - Barchart.com
Amgen Shares Acquired by Lbp Am Sa - National Today
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Eli Lilly and Company, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
KBC Group NV Has $187.27 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Lbp Am Sa - MarketBeat
Amgen Extends Cuala GAA Title Sponsorship Through 2029 - Sport for Business
Amgen Inc. $AMGN Shares Purchased by Farther Finance Advisors LLC - MarketBeat
Amgen Inc. $AMGN Shares Bought by Cwm LLC - MarketBeat
AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill
Amgen Inc. stock (US0311621009): Is its biotech innovation edge strong enough for steady gains? - AD HOC NEWS
2 Reasons to Like AMGN and 1 to Stay Skeptical - Yahoo Finance
Amgen Inc. stock (US0311621009): Is its biotech innovation edge strong enough to unlock new upside? - AD HOC NEWS
Amgen And Zai Lab Trial Tests DLL3 Combo As Valuation Looks Undemanding - Yahoo Finance
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to sustain long-term growth? - AD HOC NEWS
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to drive new upside? - AD HOC NEWS
Amgen And Zai Lab DLL3 Alliance Adds New Dimension To Oncology Story - simplywall.st
Assetmark Inc. Increases Stake in Amgen Inc. - National Today
Assetmark Inc. Buys 14,341 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
AMGN Maintained by UBS -- Price Target Raised to $400 - GuruFocus
Amgen (NASDAQ:AMGN) Price Target Raised to $400.00 - MarketBeat
Morgan Stanley Raises Amgen (AMGN) Target Ahead of Q1, Truist Lifts Outlook on Pipeline Strength - Insider Monkey
‘Community Day Presented by Amgen’ Mobilizes Volunteers to Touch Up Greater Los Angeles Ahead of FIFA World Cup 2026 - Amgen
Beat the Market the Zacks Way: FirstEnergy, Seanergy Maritime, Amgen in Focus - Yahoo Finance
HBW Advisory Services LLC Has $2.07 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Settles Denosumab Biosimilar Lawsuits with Henlius and Organon - National Today
Amgen and BeOne Medicines get Chinese approval for small cell lung cancer drug - Mugglehead Investment Magazine
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Option Exercise |
169.19 |
54,792 |
9,270,143 |
107,119 |
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Sale |
379.12 |
54,792 |
20,772,595 |
76,618 |
0.12%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):